US regulator approves Johnson & Johnson’s immune disorder drug
HQ Team April 30, 2025: Johnson & Johnson’s immune disorder drug has been approved by the US Food and Drug Administration for the.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team April 30, 2025: Johnson & Johnson’s immune disorder drug has been approved by the US Food and Drug Administration for the.
HQ Team April 29, 2025: British-Swedish pharmaceutical company AstraZeneca Plc. has discontinued its prostate cancer trial as it failed to meet the goal.
HQ Team April 29, 2025: Germany’s Merck KGaA, is set to acquire biopharmaceutical company SpringWorks Therapeutics Inc. for $3.9 billion in cash to.
HQ Team April 27, 2025: Italfarmaco SpA., a privately held Italian pharmaceutical and chemical company, received a recommendation for the conditional marketing in.
HQ Team April 27, 2025: The European Medicines Agency has granted a marketing authorisation in the EU for Amgen Inc.’s medicine for treating.
HQ Team April 27, 2025: Johnson & Johnson’s investigational treatment to help people with a specific type of early-stage bladder cancer has shown.
HQ Team April 26, 2025: Uganda declared the Ebola disease outbreak, which started three months ago, has ended, according to the World Health.
HQ Team April 26, 2025: Amgen Inc. will expand its Ohio biomanufacturing facility for $900 million, after a recent move to invest $1 billion to.
HQ Team April 23, 2025: A UN agency, the Stop TB Partnership’s Global Drug Facility (GDF), cut the price of pretomanid, a key.
HQ Team April 23: Bristol Myers Squibb’s investigational oral drug for treating schizophrenia in adults failed in its main goal to treat symptoms.
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com